Relationship of fetuin-A with glomerular filtration rate and endothelial dysfunction in moderate-severe chronic kidney disease

Journal of Nephrology

Volumn 23, Issue 1, 2010, Pages 62-69

  Cottone, Santina ^a   Palermo, Alessandro ^a   Arsena, Rosalia ^a   Riccobene, Raffella ^a   Guarneri, Marco ^a   Mulè, Giuseppe ^a   Tornese, Francesca ^a   Altieri, Chiara ^a   Vaccaro, Francesco ^a   Previti, Antonio ^a   Cerasola, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Chronic kidney disease; Endothelin 1; Fetuin A; Interleukin 6

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM; ENDOTHELIN 1; FETUIN A; INTERLEUKIN 6; PARATHYROID HORMONE; PHOSPHORUS;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SEX;

AGED; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INTERLEUKIN-6; KIDNEY DISEASES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX;

EID: 77249140495     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361:827-833.
2. Heiss A, DuChesne A, Denecke B, et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem. 2003;278:13333-13341.
3. Ix JH, Chertow GM, Shlipak MG, Brandeburg VM, Ketteler M, Whooley MA. Fetuin-A and kidney function in persons with coronary artery disease: data from the Heart and Soul Study. Nephrol Dial Transplant. 2006;21:2144-2151.
4. Ix JH, Shlipak MG, Sarnak MJ, et al. Fetuin-A is not associated with mortality in chronic kidney disease. Kidney Int. 2007;72:1394-1399.
5. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. 2006;113:1760-1767.
6. Caglar K, Yilmaz MI, Saglam M, et al. Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation. 2007;83:392-397.
7. Caglar K, Yilmaz MI, Saglam M, et al. Serum fetuin-A concentration and endothelial dysfunction in chronic kidney disease. Nephron Clin Pract. 2008;108:c233-c240.
8. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
9. Deanfield J, Donald A, Ferri C, et al; Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction: Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:7-17.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 1):S1-S266.
11. Levey AS, Greene T, Kusek J, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:155A.
12. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105-1187.
13. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
14. Cottone S, Nardi E, Mulè G, et al. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol. 2007;67:209-216.
15. Mehrotra R, Westenfeld R, Christenson P, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 2005;67:1070-1077.
16. Nigam A, Mitchell GF, Lambert J, Tardif JC. Relation between conduit vessel stiffness (assessed by tonometry) and endothelial function (assessed by flow-mediated dilatation) in patients with and without coronary heart disease. Am J Cardiol. 2003;92:395-399.
17. Budoff MJ, Flores F, Tsai J, Frandsen T, Yamamoto H, Takasu J. Measures of brachial artery distensibility in relation to coronary calcification. Am J Hypertens. 2003;16:350-355.
18. Ikeda U, Yamamoto K, Maeda Y, Shimpo M, Kanbe T, Shimada K. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension. 1997;29:65-69.
19. Jones GT, Van Rij AM, Solomon C, Thomson IA, Packer SG. Endothelin-1 is increased overlying atherosclerotic plaques in human arteries. Atherosclerosis. 1996;124:25-35.
20. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
21. Vuurmans TJ, Boer P, Koomans HA. Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. Hypertension. 2003;41:1253-1258.
22. McEniery CM, Qasem A, Schmitt M, Avolio AP, Cockcroft JR, Wilkinson IB. Endothelin-1 regulates arterial pulse wave velocity in vivo. J Am Coll Cardiol. 2003;42:1975-1981.
23. Best PJ, McKenna CJ, Hasdai D, Holmes DR Jr, Lerman A. Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation. 1999;99:1747-1752.
24. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:1890-1896.
25. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens. 1998;16:1081-1098.
26. Cottone S, Vadalà A, Mangano MT, et al. Endotheliumderived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am J Hypertens. 2000;13:172-176.
27. Caglar K, Yilmaz MI, Saglam M, et al. Short-term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol. 2008;3:61-68.
28. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
29. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
30. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentrations of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-1772.
31. Lee WY, Allison MA, Kim DJ, Song CH, Barrett-Connor E. Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). Am J Cardiol. 2007;99:99-102.
32. Noto D, Cottone S, Cefalù B, et al. Interleukin 6 plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography. Thromb Haemost. 2007;98:1362-1367.